INSM
$30.22
Insmed
($.52)
(1.69%)
INSM
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.64)
Revenue:  N/A
Thursday
Nov 5
7:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when INSM reports earnings?
Beat
Meet
Miss

Where is INSM's stock price going from here?
Up
Flat
Down
Stock chart of INSM
Analysts
Summary of analysts' recommendations for INSM
Score
Grade
Pivots
Resistance
$34.97
$33.51
$32.12

$30.66

Support
$29.28
$27.82
$26.43
Tweet
Growth
Description
Insmed Pharmaceuticals is a development stage pharmaceutical company that is developing drugs to treat metabolic and endocrine diseases associated with insulin resistance. The company's first drug candidate, INS-1, is currently targeted towards the treatment of type 2 diabetes and polycystic ovary syndrome. The company is currently conducting multi-center phase II clinical trials for both indications. The company's objective is to establish a leading position in the treatment of metabolic and endocrine diseases.
Peers
InterCeptRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalJohnson & JohnsonZoetisBristol-Myers SquibbUltragenyx PharmaceuticalCatalentMerck & Co.